Twice-weekly portable electrocardiogram screening

Twice-weekly portable electrocardiogram screening has been studied in 1 paper since 2023: 1 trial in people. The newest paper, May 3, 2023: “Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study”.

Intervention

1 paper studies it6 findingsUpdated

See all 1 papers on twice-weekly portable electrocardiogram screening

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Over the full period of follow-up, although detection of AF was 38.7% greater in the iECG group compared with RC, this difference was not statistically significant.”
Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF studyEuropean heart journal open2023doi:10.1093/ehjopen/oead047

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funders: AliveCor and 1 more
  • Human trial1

Studies in people

1 study gave twice-weekly portable electrocardiogram screening to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on atrial fibrillation+38.7%

no change: Has no effect on stroke

no change: Has no effect on mortality

Randomized trial4.2 years997 people53.3% femalemean age 72.6 ± 5.4 yearsPatients over 65 years with a CHADS-VASc score ≥ 2, without a known diagnosis of AF, known contraindication to anticoagulation or permanent cardiac pacing implantationEuropean heart journal open, May 3, 2023

What did studies of twice-weekly portable electrocardiogram screening find?

3

Studies of twice-weekly portable electrocardiogram screening measured 3 outcomes: mortality, stroke and atrial fibrillation.

Mortality

no changein humans1HR 1.07

1 study
  1. Twice-weekly portable electrocardiogram screening showed no clear effect on mortality in humans.

    “There was no difference in the number of deaths, strokes, or TIA between the two groups.”

    Human trial4.2 yearsn = 997

    Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study

    European heart journal open

  2. Twice-weekly portable electrocardiogram screening showed no clear effect on mortality in humans (HR 1.07, 95% CI 0.66-1.73).

    “HR 1.07, 95% CI 0.66-1.73”

    Human trialmedian 4.2-year

    Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study

    European heart journal open

Stroke

no changein humans1HR 0.92

1 study
  1. Twice-weekly portable electrocardiogram screening showed no clear effect on stroke in humans.

    “There was no difference in the number of deaths, strokes, or TIA between the two groups.”

    Human trial4.2 yearsn = 997

    Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study

    European heart journal open

  2. Twice-weekly portable electrocardiogram screening showed no clear effect on stroke in humans (HR 0.92, 95% CI 0.54-1.54).

    “No differences were seen in the number of strokes/systemic embolisms or deaths between the two groups (HR 0.92, 95% CI 0.54-1.54”

    Human trialmedian 4.2-year

    Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study

    European heart journal open

More on Stroke

Atrial fibrillation

no changein humans1+39%

1 study
  1. Twice-weekly portable electrocardiogram screening showed no clear effect on atrial fibrillation in humans (+38.7%).

    “Over the full period of follow-up, although detection of AF was 38.7% greater in the iECG group compared with RC, this difference was not statistically significant.”

    Human trial4.2 yearsn = 997

    Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study

    European heart journal open

More on Atrial fibrillation

What is twice-weekly portable electrocardiogram screening linked with?

1

Studies link twice-weekly portable electrocardiogram screening with acute coronary syndrome.

Acute coronary syndrome

downin humans1

1 study
  1. Twice-weekly portable electrocardiogram screening lowers the risk of acute coronary syndrome in humans (10 vs. 21).

    “Participants in the iECG care group were less likely to have an acute coronary syndrome event during the follow-up period than in the RC group (10 vs. 21, P = 0.044; ).”

    Human trial4.2 yearsn = 997

    Incident atrial fibrillation and adverse clinical outcomes during extended follow-up of participants recruited to the remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study

    European heart journal open

More on Acute coronary syndrome

Latest